Navigation Links
Indonesia's Pharmaceutical companies Get Boost in Competitive Advantage from Launch of Newport Horizon Premium and IDRAC Solutions by Thomson Reuters
Date:8/25/2008

Industry Leader in Generic Market Information Offers Single Authoritative Source of API Sourcing and Global Regulatory Intelligence to Indonesia's

Generics and API Manufacturers

JAKARTA, Indonesia, Aug. 26 /Xinhua-PRNewswire/ -- Indonesia's generics and API (Active Pharmaceutical Ingredient) manufacturers get boost in competitive advantage from launch of two solutions in the market by the Scientific business of Thomson Reuters, the world's leading source of intelligent information for businesses and professionals. Newport Horizon Premium(TM) is designed specifically for professionals working in product selection, business development, competitive intelligence and API (Active Pharmaceutical Ingredient) sourcing. IDRAC(R) is a single comprehensive source of global regulatory intelligence. Their use by generic and OTC (Over the Counter) pharmaceutical companies and API manufacturers in Indonesia will enable them to develop products more quickly, keep up with changing global regulatory requirements and speed product registration and commercialisation, thereby expanding their business footprint in Asia and beyond.

The two solutions can help provide a competitive boost to Indonesia's pharmaceutical industry which is forecast to reach US$3.75bn in value by 2012 according to Business Monitor International in April 2008.

Said Mr. Wong Woei Fuh, Commercial Director Asia Pacific, Scientific business of Thomson Reuters, "To stay competitive in the generics market, pharmaceutical companies and API manufacturers in Indonesia have a critical need for authoritative market information as well as time and money-saving API sourcing solutions. Customers will benefit from our one-stop global resource of intelligence which will help them improve productivity, accelerate time to market and gain that competitive edge to expand their footprint globally, part of the government's drive to promote the local pharmaceuticals industry. As the in
'/>"/>

SOURCE Thomson Reuters
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine news :

1. Mylan Commences Tender Offers and Consent Solicitations for Its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015 in Connection With Its Proposed Acquisition of Mercks Generic Pharmaceutical Business
2. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
3. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
4. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
5. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
6. National Pharmaceutical Council Announces New Strategic Focus, Search for New Leadership
7. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Coreg(R)
8. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
9. Par Pharmaceutical Files Form 10-K for 2006 -- Company to Hold First Analysts Meeting September 28, 2007
10. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
11. Pharmaceutical Manufacturing Quality: Optimizing Your Internal Process for FDA Compliance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2009)... SUNDAY, Dec. 6 (HealthDay News) -- Early roots of the ... that lived thousands or millions of years ago, new research ... bit of a tiger,s genetic material, scientists say, and a ... day. That tiger, in fact, may have bitten a monkey, ... to its infection of humans. , The finding shouldn,t lead ...
(Date:12/6/2009)... 2009 A new study provides welcome news for ... thromboembolism (VTE). , The condition is estimated to ... occurs when an abnormal clot forms in a vein ... swelling. In some cases, the clot may detach from ... to the lungs, causing a potentially fatal condition known ...
(Date:12/5/2009)... have been significant scientific advances in the field of ... better understanding of how certain diseases progress in order ... the best care. Research presented today at the 51st ... optimal induction therapies for managing multiple myeloma, the importance ...
(Date:12/5/2009)... , , SATURDAY, Dec. 5 (HealthDay News) -- They,re not ... bad reactions to certain holiday traditions and need to ... to the American College of Allergy, Asthma and Immunology ... may choose to decorate with artificial plants, but both ...
(Date:12/5/2009)... most unusual places, and to do everything from growing mushrooms, making wine ... ... Who would have thought that your wine, water and vegetables would have ... a new line of turbines, for industry end users, not wind farms. ...
Breaking Medicine News(10 mins):Health News:AIDS May Date Back to Ancient Tiger 2Health News:New drug shows promise for those with clotting disorders: McMaster researcher 2Health News:New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard-To-Treat Forms of Blood Cancer 2Health News:New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard-To-Treat Forms of Blood Cancer 3Health News:New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard-To-Treat Forms of Blood Cancer 4Health News:New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard-To-Treat Forms of Blood Cancer 5Health News:New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard-To-Treat Forms of Blood Cancer 6Health News:New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard-To-Treat Forms of Blood Cancer 7Health News:New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard-To-Treat Forms of Blood Cancer 8Health News:Keep Asthma, Allergies at Bay for the Holidays 2Health News:Distributor Announces New Applications for Wind Turbines 2Health News:Distributor Announces New Applications for Wind Turbines 3
... Offers Fun and Wallet-Friendly Tips for Enjoying the ... makers of BENADRYL(R) and the National Park Foundation ... everyone, including people with allergies, to pledge to ... and family.(Photo: http://www.newscom.com/cgi-bin/prnh/20090420/NY01084 ...
... 25, 2009 BALTIMORE, April 20 The first annual ... gaining national support. The day is meant to raise ... the Meningococcal disease. "We recognize the dangers of meningitis ... said Fran Lessans, CEO of Passport Health, the largest ...
... Spring with Fresh, New Colors from Z-CoiL® , ... Albuquerque, NM (PRWEB) ... of our unique line of Pain Relief Footwear® products, ushers in spring ... Women. There is currently only a limited supply of these new athletic ...
... TOKYO, April 20 /PRNewswire-Asia/ -- Shanghai ChemPartner Co., ... Kagaku Kenkyusho Co.,Ltd. (SKK), a pharmaceutical company headquartered ... into a strategic alliance. The partnership,was formed as ... SKK to target the,Asian market, in step with ...
... could prevent radiation-induced leukemia, according to data presented at ... 2009. , Alexandra Miller, Ph.D., a senior scientist ... research is designed to help military and space agency ... risky levels of radiation than the general population. However, ...
... can help control appetite and weight , , SUNDAY, April 19 ... on snacking by chewing more sugarless gum. , ... three hours after a standard lunch and were told they ... One afternoon the participants also chewed sugarless gum for 15 ...
Other Medicine News:Health News:The Makers of BENADRYL(R) and the National Park Foundation Encourage People to Pledge to Spend More Time Enjoying Outdoor Moments 2Health News:The Makers of BENADRYL(R) and the National Park Foundation Encourage People to Pledge to Spend More Time Enjoying Outdoor Moments 3Health News:The Makers of BENADRYL(R) and the National Park Foundation Encourage People to Pledge to Spend More Time Enjoying Outdoor Moments 4Health News:The Makers of BENADRYL(R) and the National Park Foundation Encourage People to Pledge to Spend More Time Enjoying Outdoor Moments 5Health News:First Annual World Meningitis Day Gaining National Support 2Health News:Got the Blues? Get Z-CoiL Pain Relief Shoes 2Health News:Shanghai ChemPartner and SKK Announce Strategic Alliance 2Health News:Gum Chewing May Cut Craving for Snacks 2
(Date:12/4/2009)... PharmAthene, Inc. (NYSE Amex: PIP ), a ... chemical threats, announced today that the Company is ... of Valortim® in an inhalation anthrax model in ... data are being presented during an oral session ...
(Date:12/4/2009)... HOUSTON, Dec. 4 OrthoAccel Technologies, Inc., developers ... an acceleration device to enhance orthodontics, announced the ... by PennWell Corporation , a leader in ... dentistry. The course focuses on patient views ...
(Date:12/4/2009)... Drs. Neal Shore and E. David Crawford presented results ... of secondary end points of biochemical recurrence rate in ... for injection) or monthly leuprolide in prostate cancer patients ... patients who received FIRMAGON 240/80 mg/month had a recurrence ...
Breaking Medicine Technology:PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop 2PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop 3PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop 4PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop 5PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop 6AcceleDent Science is Showcased in New Continuing Education Course Published by PennWell 2AcceleDent Science is Showcased in New Continuing Education Course Published by PennWell 3AcceleDent Science is Showcased in New Continuing Education Course Published by PennWell 4Degarelix (FIRMAGON(R)) vs Leuprolide (Lupron Depot(R)) in Patients With Advanced Prostate Cancer: Further Analysis From a Phase III Pivotal Trial 2Degarelix (FIRMAGON(R)) vs Leuprolide (Lupron Depot(R)) in Patients With Advanced Prostate Cancer: Further Analysis From a Phase III Pivotal Trial 3Degarelix (FIRMAGON(R)) vs Leuprolide (Lupron Depot(R)) in Patients With Advanced Prostate Cancer: Further Analysis From a Phase III Pivotal Trial 4Mingling Martinis 26amp 3B Mysterious Murder Masquerade at the Whitney to Benefit Carnival of Care 59087 1Mingling Martinis 26amp 3B Mysterious Murder Masquerade at the Whitney to Benefit Carnival of Care 59087 2BayCare Behavioral Health and Homeless Emergency Project Receive Federal Grant to Help Break the Cycle of Homelessness 59084 1BayCare Behavioral Health and Homeless Emergency Project Receive Federal Grant to Help Break the Cycle of Homelessness 59084 2BayCare Behavioral Health and Homeless Emergency Project Receive Federal Grant to Help Break the Cycle of Homelessness 59084 3Coverall Named Among 50 Top Franchises for Minorities for Third Consecutive Year 59081 1Coverall Named Among 50 Top Franchises for Minorities for Third Consecutive Year 59081 2
For the qualitative detection of cardiac troponin I (cTnl) in human whole blood and serum specimens...
For the qualitative detection of antibodies to Treponema pallidum in human serum, plasma and whole blood specimens...
For the qualitative detection of antibodies to HIV-1 and HIV-2 in human serum, plasma and whole blood specimens...
... Pacemaker Follow-Up Solution makes convenience and ... our Cardiac Monitoring Center, qualified professionals ... seven days a week for Pacemaker ... time they experience a problem or ...
Medicine Products: